Blue Horizon International Announces Plans to Offer Stock to the Public: Invest in the Future of Healthcare
Blue Horizon International (BHI) is excited to announce plans to offer stock to the public in the coming months. This move is a significant step for the company, which has been at the forefront of biotechnology innovation in the field of regenerative medicine. BHI offers the highest quality stem cell treatments for various conditions, backed by unparalleled 10-year safety and efficacy data.
As a healthcare consulting company, BHI’s unique concept combines therapy, research, and philanthropy. They provide the highest quality care and service available in surgical & medical therapies globally, and the most advanced technologies currently available in areas such as stem cell therapy, regenerative medicine, and cancer immunotherapy, and also provide resources for those who are medically underserved. BHITS’s research studies are designed to measure the safety and efficacy of intravenous, intra-articular, and intrathecal stem cell therapies. Its comprehensive stem cell protocols employ well-targeted combinations of autologous bone marrow stem cells, stem cells derived from Wharton’s jelly, autologous adipose stem cells, and allogeneic human umbilical cord stem cells that treat various conditions such as spinal cord injury, traumatic brain injury, and chronic inflammation.
The BHITS team is currently working on stem cell research projects which have the potential to cure some of the most difficult-to-cure medical conditions. They are working on multiple projects which are in the different stages of U.S. FDA processes such as pre-clinical, clinical stage I, clinical stage II, and so on. Some of these projects have already provided invaluable data regarding the effectiveness & efficacy of stem cell therapies and they will be approved by the U.S. FDA very soon. BHITS is the only company that has published several peer-reviewed stem cell research papers and is the only company to get U.S. FDA approval to treat patients with stem cell therapies. It also has a global & innovative business model which has enabled it to test its therapies in the U.S. as well as global locations such as Jamaica & Slovakia and bring back the data to the U.S. for achieving quicker approvals from the U.S. FDA.
Offering stock to the public will provide BHI with additional resources to continue its cutting-edge research and development in the field of regenerative medicine. It also provides investors with the opportunity to be a part of a company that is at the forefront of medical advancement and the future of healthcare. The company’s management team will be releasing more information about the stock offering in the coming months, including details on the pricing, the number of shares available, and the process for investing. This is an exciting opportunity for anyone who is interested in investing in a company that is dedicated to improving the lives of patients through advanced therapies and research.
